Table 1. Patients with grades 2 to 5 CTCAE toxicities at 12 weeks.
| FOLFOX treated | XELOX treated | ||||
|---|---|---|---|---|---|
| n = 385 (%) | + cetuximab n = 360 (%) | n = 707 (%) | + cetuximab n = 348 (%) | ||
| Any toxicity | 237 (61) | 275 (76) | 430 (61) | 226 (65) | |
| Individual toxicities | |||||
| Diarrhoea | 78 (20) | 109 (30) | 165 (23) | 123 (35) | |
| Neutropenic sepsis | 24 (8) | 39 (16) | 5 (0.7) | 1 (0.3) | |
| Peripheral neuropathy | 43 (11) | 30 (8) | 110 (16) | 44 (13) | |
| Hand-foot syndrome | 9 (2) | 56 (16) | 53 (8) | 56 (16) | |
| Neutropenia | 100 (26) | 119 (33) | 36 (5) | 6 (2) | |
| Lethargy | 130 (34) | 126 (35) | 258 (36) | 103 (30) | |
| Stomatitis | 48 (12) | 102 (28) | 32 (5) | 29 (8) | |
| Nausea | 41 (11) | 47 (13) | 142 (20) | 68 (20) | |
| Vomiting | 25 (6) | 34 (9) | 87 (12) | 35 (10) | |
| Rash | 5 (1) | 196 (54) | 11 (2) | 166 (48) | |
Note: Percentage of patients in parentheses. We had 70% power to detect a mean OR of 4.3 (range, 3-6) for any toxicity and 5.9 (2-39) for individual toxicities (Supplementary Table 3). For neutropenic sepsis in patients treated with XELOX and XELOX + cetuximab, neutropenia in patients treated with XELOX + cetuximab and rash in patients treated with FOLFOX, we had insufficient power to perform the genome-wide association studies (GWASs); therefore, in total, we conducted 40 GWASs.